The N-terminal sequence of the Smac/DIABLO
protein is known to be involved in binding to the BIR3 domain of the
anti-apoptotic proteins IAPs, antagonizing their action. Short
peptides and
peptide mimetics based on the first 4-residues of Smac/DIABLO have been demonstrated to re-sensitize resistant
cancer cells, over-expressing IAPs, to apoptosis. Based on the well-defined structural basis for this interaction, a small focused library of C-terminal capped Smac/DIABLO-derived
peptides was designed in silico using docking to the XIAP BIR3 domain. The top-ranked computational hits were conveniently synthesized employing Solid Phase Synthesis (SPS) on an
alkane sulfonamide 'Safety-Catch' resin. This novel approach afforded the rapid synthesis of the target
peptide library with high flexibility for the introduction of various C-terminal
amide-capping groups. The library members were obtained in high yield (>65%) and purity (>85%), upon nucleophilic release from the activated resin by treatment with various
amine nucleophiles. In vitro
caspase-9 activity reconstitution assays of the
peptides in the presence of the recombinant BIR3-domain of human XIAP (500nM) revealed N-methylalanyl-tertiarybutylglycinyl-4-(R)-phenoxyprolyl-N-biphenylmethyl carboxamide (11a) to be the most potent XIAP BIR3 antagonist of the series synthesized inducing 93% recovery of
caspase-9 activity, when used at 1μM concentration. Compound (11a) also demonstrated moderate cytotoxicity against the
breast cancer cell lines MDA-MB-231 and MCF-7, compared to the Smac/DIABLO-derived wild-type
peptide sequences that were totally inactive in the same cell lines.